Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Case Report: Older Woman With Metastatic Bladder Cancer Responds to Pembrolizumab

By: Vanessa A. Carter, BS
Posted: Monday, October 11, 2021

Michael Maroules, MD, of Saint Joseph’s University Medical Center, Paterson, New Jersey, and colleagues presented a case study in the Journal of Investigative Case Reports featuring a complete response to the immune checkpoint inhibitor pembrolizumab in an older patient with metastatic bladder cancer who was ineligible for chemotherapy. These investigators explained that although platinum-based chemotherapy remains the first-line treatment of bladder cancer, the administration of pembrolizumab has often achieved complete responses in individuals with various malignancies.

An 83-year-old woman presented to the emergency department with lower abdominal pain, beginning 1 month prior that progressively had become worse. A CT scan of the pelvis and abdomen uncovered a large hydroureter, hydronephrosis mass in the base of the bladder, along with a 4.6 cm x 4.7 cm mass in the middle of the left common femoral artery. A transurethral resection of the tumor revealed a large necrotic mass on the left side of the bladder, which was identified as high-grade metastatic urothelial carcinoma.

The patient’s eligibility for chemotherapy was hindered due to her performance status and age, so pembrolizumab was initiated. The woman received seven cycles of pembrolizumab every 3 weeks but eventually presented with difficulty breathing, and a chest CT scan revealed pneumonitis. The patient permanently stopped pembrolizumab and began steroids, later being discharged home.

The woman continued her follow-up as an outpatient off therapy and repeated abdomen, chest, and pelvis CT scans 6 months after the last treatment dose. At this time, the patient showed no evidence of metastatic disease in her abdomen, chest, or pelvis, suggesting a complete response to pembrolizumab.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.